Gene therapy is currently in the public spotlight. Several gene therapy products, including
oncolytic virus (OV), which predominantly replicates in and kills cancer cells, and COVID-19 …

Gene therapy has promised to be a highly effective antitumor treatment by introducing a
tumor suppressor gene or the abrogation of an oncogene. Among the potential therapeutic …

Ad5-delta-24-RGD is currently the most clinically advanced recombinant adenovirus (rAd)
for glioma therapy. We constructed a panel of fiber-modified rAds (Ad5RGD, Ad5/3, Ad5/35 …

Adenovirus vectors have attracted considerable interest over the past decade, with ongoing
clinical development programs for applications ranging from replacement therapy for protein …

E2F acts as a transcriptional repressor when bound to unphosphorylated RB during the G 1
or G 0 phase. Upon phosphorylation, E2F is released from the E2F–RB complexes to …

Novel approaches to treatment of malignant glioma, the most frequently occurring primary
brain tumor, have included the use of a wide range of oncolytic viral vectors. These vectors …

Oncolytic virus (OV) therapy utilizes replication-competent viruses to kill cancer cells, leaving
non-malignant cells unharmed. With the first US Food and Drug Administration-approved …

Oncolytic adenoviruses are promising anticancer agents due to their ability to self-amplify at
the tumor mass. However, tumor stroma imposes barriers difficult to overcome by these …

Conditionally replicating adenoviruses (CRAds) have many advantages as agents for
cancer virotherapy and have been safely used in human clinical trials. However, replicating …

Approaches to improve the oncolytic potency of replication-competent adenoviruses include
the insertion of therapeutic transgenes into the viral genome. Little is known about the levels …